Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae

Journal of Infectious Diseases

Volumn 207, Issue 5, 2013, Pages 786-793

  Hirsch, Elizabeth B ^a,b   Guo, Beining ^a,d   Chang, Kai Tai ^a   Cao, Henry ^a   Ledesma, Kimberly R ^a   Singh, Manisha ^c   Tam, Vincent H ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d FUDAN UNIVERSITY   (China)

Author keywords

AmpC; beta lactamases; combined killing; pharmacodynamics; synergism

Indexed keywords

AMIKACIN; CARBAPENEMASE; DORIPENEM; ERTAPENEM; LEVOFLOXACIN; PLACEBO; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MATHEMATICAL MODEL; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SURVIVAL; VALIDATION STUDY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; BACTERIAL PROTEINS; BETA-LACTAMASES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LUNG; MICE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME;

EID: 84873622347     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis766     Document Type: Article

References (39)

1. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009; 9:228-36
2. Srinivasan A, Patel JB. Klebsiella pneumoniae carbapenemase-producing organisms: An ounce of prevention really is worth a pound of cure. Infect Control Hosp Epidemiol 2008; 29:1107-9
3. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: Epidemiology and prevention. Clin Infect Dis 2011; 53:60-7
4. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenemresistant Klebsiella pneumoniae in New York City: A new threat to our antibiotic armamentarium. Arch Intern Med 2005; 165:1430-5
5. Kitchel B, Rasheed JK, Patel JB, et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: Clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 2009; 53:3365-70
6. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenemhydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45:1151-61
7. Endimiani A, Hujer AM, Perez F, et al. Characterization of blaKPCcontaining Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother 2009; 63:427-37
8. Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-betalactamase-producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008; 52:570-3
9. Bratu S, Mooty M, Nichani S, et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: Epidemiology and recommendations for detection. Antimicrob Agents Chemother 2005; 49:3018-20
10. Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: Molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005; 56:128-32
11. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): An emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010; 65:1119-25
12. Woodford N, Tierno Jr. P.M., Young K, et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A betalactamase, KPC-3, in a New York Medical Center. Antimicrob Agents Chemother 2004; 48:4793-9
13. Le J, McKee B, Srisupha-Olarn W, Burgess DS. In vitro activity of carbapenems alone and in combination with amikacin against KPCproducing Klebsiella pneumoniae. J Clin Med Res 2011; 3:106-10
14. Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase- producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011; 55:3002-4
15. Souli M, Galani I, Boukovalas S, et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob Agents Chemother 2011; 55:2395-7
16. Wiskirchen DE, Koomanachai P, Nicasio AM, Nicolau DP, Kuti JL. In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase. Antimicrob Agents Chemother 2011; 55:1420-7
17. Pournaras S, Vrioni G, Neou E, et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents 2011; 37:244-7
18. Queenan AM, Shang W, Flamm R, Bush K. Hydrolysis and inhibition profiles of {beta}-lactamases from molecular classes A to D with doripenem, imipenem and meropenem. Antimicrob Agents Chemother 2010; 54:565-9
19. Urban C, Mariano N, Rahal JJ. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrugresistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother 2010; 54:2732-4
20. Landman D, Bratu S, Quale J. Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae. J Med Microbiol 2009; 58:1303-8
21. Hirsch EB, Chang KT, Lasco TM, Caeiro JP, Tam VH. Emergence of KPC-producing Klebsiella pneumoniae in Texas. Diagn Microbiol Infect Dis 2011; 69:234-5
22. Lim TP, Ledesma KR, Chang KT, et al. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2008; 52: 2898-904
23. Tam VH, Schilling AN, Lewis RE, Melnick DA, Boucher AN. Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. Antimicrob Agents Chemother 2004; 48: 4315-21
24. Yuan Z, Ledesma KR, Singh R, Hou J, Prince RA, Tam VH. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model. J Infect Dis 2010; 201:889-97
25. Tam VH, Ledesma KR, Schilling AN, et al. In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing. Diagn Microbiol Infect Dis 2009; 64:427-33
26. Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991; 27 (SUPPLC):29-40
27. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillinclavulanate against Streptococcus pneumoniae: Application to breakpoint determinations. Antimicrob Agents Chemother 1998; 42:2375-9
28. Monton C, Torres A, El-Ebiary M, Filella X, Xaubet A, de la Bellacasa JP. Cytokine expression in severe pneumonia: A bronchoalveolar lavage study. Critical Care Medicine 1999; 27:1745-53
29. Davies TA, Marie Queenan A, Morrow BJ, et al. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09. J Antimicrob Chemother 2011; 66:2298-307
30. Landman D, Salamera J, Singh M, Quale J. Accuracy of carbapenem nonsusceptibility for identification of KPC-possessing Enterobacteriaceae by use of the revised CLSI breakpoints. J Clin Microbiol 2011; 49:3931-3
31. Endimiani A, Choudhary Y, Bonomo RA. In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother 2009; 53:3599-601
32. Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VH. In vitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother 2012; 56:3753-7
33. Young K, Raghoobar SL, Hairston NN, et al. In vitro activity of the class A and C β-lactamase inhibitor MK-7655. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 12-15, 2010. Boston, MA. Abstract F1-2139
34. Bulik CC, Nicolau DP. In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemaseproducing Klebsiella pneumoniae. Antimicrob Agents Chemother 2010; 54:4112-5
35. Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti JL. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2010; 54:804-10
36. King TC, Schlessinger D, Krogstad DJ. The assessment of antimicrobial combinations. Rev Infect Dis 1981; 3:627-33
37. Rand KH, Houck HJ, Brown P, Bennett D. Reproducibility of the microdilution checkerboard method for antibiotic synergy. Antimicrob Agents Chemother 1993; 37:613-5
38. Tan TY, Lim TP, Lee WH, Sasikala S, Hsu LY, Kwa AL. In vitro antibiotic synergy in extensively drug-resistant Acinetobacter baumannii: The effect of testing by time-kill, checkerboard, and Etest methods. Antimicrob Agents Chemother 2011; 55:436-8
39. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol 2009; 30:1180-5